1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

27 Feb 2024
Admin
News Article

Immunofoco Gets Approval to Begin Trials for IMC001

Immunofoco gets US FDA & China CDE approvals to begin clinical trial of IMC001 for EpCAM CAR-T targeted advanced solid tumours

Overview

Immunofoco, a company dedicated to developing cell therapy products for solid tumours, announced a significant milestone, that following the approval by the CDE in China for the clinical trial application of IMC001, an EpCAM-targeting autologous CAR-T cell product for infusion, it also received the IND approval from the US FDA, for the treatment of EpCAM-positive advanced gastrointestinal tumours, including but not limited to advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ).

About EpCAM

EpCAM serves as a biomarker for circulating tumour cells (CTCs), which is highly expressed in both primary and metastatic lesions of gastrointestinal tumours, while its expression in normal tissues is low.
t has been identified as a promising therapeutic target for GI tumours with a wide range of expandable indications.
MC001, through targeting EpCAM, is the first CAR-T product utilizing the strategy of ""curing the solid tumours by treating them as hematologic malignancies "".
In August 2023, the product was granted Orphan Drug Designation (ODD) by the US FDA.

Trial Results

The impressive clinical results of IMC001 have been shared at prestigious medical conferences, including being orally presented at the annual meeting of the European Society of Medical Oncology (ESMO) in 2022 and updated during the American Society of Clinical Oncology (ASCO) in 2023.

Future Process

As of January 31, 2024, in the IIT clinical trial for advanced gastric cancer, a safe and effective recommended dose has been identified, with two (2) out of five (5) patients in this dose group achieved partial remission (PR), with an overall response rate (ORR) of 40%. Among them, one PR patient underwent a successful radical surgery for gastric cancer 30 weeks after a single infusion of IMC001 and is still alive 85 weeks after IMC001 treatment. Another PR patient exhibited a 48% reduction in tumour size by week 16.

Words From Immunofoco

Dr. Crystal Sun, founder, chairman, and ceo of Immunofoco, expressed her congratulations and gratitude to the entire team. She highlighted the significance of Immunofoco’s achievement: securing dual IND approval for a second CAR-T product targeted for solid tumours in both the US and China.
Targeting EpCAM shows great potential for CAR-T treatment of solid tumours as it is highly expressed in primary, metastatic and circulating tumour cells.
About 90% of the patients with gastrointestinal tumours exhibit EpCAM expression, which satisfies a broader clinical need. With the US/CN approval of this IND application, IMC001 is now poised to undertake further clinical trials and forge international collaborations, positioning itself as a promising new therapeutic option for patients with advanced GI tumours on a global scale.

About Immunofoco

Immunofoco has pioneered a clinical strategy focused on “curing the solid tumours by treating them as hematologic malignancies”, addressing the challenges in solid tumour treatment, and the clinical advantages of treating hematologic malignancies.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!